| Bioactivity | RK-20448 is an ATP-competitive inhibitor of Lck, Src, KDR/VEGF2R and Tie-2 with IC50 values of 0.24, 1.19, 10.74 and 5.85 µM, respectively. RK-20448 also inhibits BLK, Csk, Fyn and Lyn with IC50 values of 0.37, 4.27, 2.03 and 0.43 µM, respectively. RK-20448 is the cis isomer of A-419259 (HY-15764)[1][2]. | ||||||||||||
| CAS | 479501-40-1 | ||||||||||||
| Formula | C29H34N6O | ||||||||||||
| Molar Mass | 482.62 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Saito Y, et al. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo. Sci Transl Med. 2013 Apr 17;5(181):181ra52. [2]. Almoyad MAA, et al. Hematopoietic cell kinase as a nexus for drug repurposing: implications for cancer and HIV therapy. J Biomol Struct Dyn. 2024 Mar 26:1-11. |